Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Citronellol [106-22-9]

Citronellol [106-22-9]

Imprimer Imprimer
Identifiez-vous
Commande minimum 2

Référence HY-W010201-500mg

Conditionnement : 500mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis[2][4][6][7].
IC50 & Target

IC50: 54.02，40.64，52.51，45.84，50.1 μg/mL (A549、NCI-H1299、NCI-H23、BT-20、PC3 cells) (Apoptosis)[6].
Cellular Effect
Cell Line Type Value Description References
HEK293 EC50
>100 μM
Compound: Citronellol
Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as increase in intracellular Ca2+ concentration by Fluo-4-AM dye based spectrofluorimetry
Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as increase in intracellular Ca2+ concentration by Fluo-4-AM dye based spectrofluorimetry
[PMID: 25455494]
HEK293 IC50
>100 μM
Compound: Citronellol
Antagonist activity against human TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-induced increase in intracellular Ca2+ concentration by Fluo-4-AM dye based spectrofluorimetry
Antagonist activity against human TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-induced increase in intracellular Ca2+ concentration by Fluo-4-AM dye based spectrofluorimetry
[PMID: 25455494]
HEK293 IC50
>100 μM
Compound: Citronellol
Antagonist activity against rat TRPA1 expressed in HEK293 cells assessed as inhibition of AITC-induced increase in intracellular Ca2+ concentration by Fluo-4-AM dye based spectrofluorimetry
Antagonist activity against rat TRPA1 expressed in HEK293 cells assessed as inhibition of AITC-induced increase in intracellular Ca2+ concentration by Fluo-4-AM dye based spectrofluorimetry
[PMID: 25455494]
HEK293 IC50
>100 μM
Compound: Citronellol
Antagonist activity against rat TRPM8 expressed in HEK293 cells assessed as inhibition of icilin-induced increase in intracellular Ca2+ concentration by Fluo-4-AM dye based spectrofluorimetry
Antagonist activity against rat TRPM8 expressed in HEK293 cells assessed as inhibition of icilin-induced increase in intracellular Ca2+ concentration by Fluo-4-AM dye based spectrofluorimetry
[PMID: 25455494]
In Vitro

Citronellol (50, 100 μg/mL, 72 h) can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways[2].
Citronellol can be used as a skin contact allergen after forming hydrogen peroxide through self oxidation[3].
Citronellol (0-100 μg/mL, 48 h) can induce necrotic apoptosis in human lung cancer cell line NCI-H1299 through the TNF-α pathway and accumulation of reactive oxygen species[6].
Citronellol (0-100 μg/mL, 48 h) exhibits cytotoxicity towards A549, NCI-H1299, NCI-H23, BT-20, and PC3 cells, with IC50 values of 54.02, 40.64, 52.51, 45.84, and 50.1 μg/mL, respectively[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Citronellol Related Antibodies

Cell Viability Assay[2].

Cell Line: SH-SY5Y human neuroblastoma cells
Concentration: 50, 100 μg/mL
Incubation Time: 72 h
Result: Improved the cell viability of SH-SY5Y cells treated with 6-OHDA, reaching levels of 96.25% and 97.56% at concentrations of 50 μ g/mL and 100 μg/mL, respectively.

Cell Cytotoxicity Assay[6].

Cell Line: NSCLC cells A549, NCI-H23, NCI-H1299, BT-20, PC3 and MCF-10A
Concentration: 0-100 μg/mL
Incubation Time: 48 h
Result: Showed toxic effects on 5 cancer cell lines, but had no effect on normal cells (MCF-10A).
In Vivo

Citronellol (25, 50, 100 mg/kg; once daily; 2 weeks; p.o.) has a cardioprotective effect on the cardiotoxicity of Doxorubicin (HY-15142A) induced myocardial ischemia in rats[1].
Citronellol (25 mg/kg; once daily; 4 weeks; p.o.) can reduce the levels of LC-3 and p62 to regulate autophagy pathway, inhibit oxidative stress and neuroinflammation, thereby exerting neuroprotective effects on Parkinson's rats[4].
Citronellol (50, 100 mg/kg; once daily; 4 days; p.o.) can protect the kidneys in rhabdomyolysis induced acute kidney injury in mice through its anti apoptotic effect[5].
Citronellol (12.5, 25, 50 mg/kg; once daily; 20 days; i.p.) exhibits anti-tumor activity in non-small cell lung cancer mice[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rat myocardial ischemia model established by intraperitoneal injection of DOX (2.5 mg/kg) (HY-15142A) 6 times every other day [1].
Dosage: 25, 50, 100 mg/kg
Administration: Oral gavage (p.o.); once daily; 2 weeks
Result: Reduced the production of cardiac antioxidant enzymes, pro-inflammatory cytokines, and lipid biomarkers, and increased the expression of anti-inflammatory cytokines.
Animal Model: Chronic Rotenone (HY-B1756) PD rat model[4].
Dosage: 25 mg/kg
Administration: Oral gavage (p.o.); once daily; 4 weeks
Result: Inhibited Rotenone (HY-B1756) induced reactive oxygen species production, lipid peroxidation, and enhanced Nrf2 expression, catalase, glutathione peroxidase, and superoxide dismutase levels in the brain.
Animal Model: A mouse model of rhabdomyolysis induced by a single intramuscular injection of 50% glycerol at a dose of 10 ml/kg [5].
Dosage: 50, 100 mg/kg
Administration: Oral gavage (p.o.); once daily; 4 days
Result: Reduced KIM-1 mRNA and myoglobin levels, as well as cleaved caspase-3 and BAX protein levels in renal tissue.
Animal Model: NSCLC nude mouse model established by subcutaneous injection of NCI-H1299 cells into the posterior abdomen of 7-week-old BALB/c (nu/nu) nude mice[6].
Dosage: 12.5, 25, 50 mg/kg
Administration: Intraperitoneal injection (i.p.); once daily; 20 days
Result: Inhibited the growth of subcutaneous tumors.
Masse moléculaire

156.27

Formule

C10H20O
CAS No.
Appearance

Liquid (Density: 0.857 g/cm3)

Color

Colorless to light yellow

SMILES

CC(CCC=C(C)C)CCO
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL (639.92 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.3992 mL 31.9959 mL 63.9918 mL
5 mM 1.2798 mL 6.3992 mL 12.7984 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (16.00 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (16.00 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 33.33 mg/mL (213.28 mM); Clear solution; Need ultrasonic
Pureté et documentation
Références